{"product_id":"bms-pestle-analysis","title":"Bristol Myers Squibb PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNavigate the external forces shaping Bristol Myers Squibb—regulatory shifts, patent cliffs, pricing pressures, and biotech innovation—and turn those insights into strategic advantage; purchase the full PESTLE analysis for a complete, actionable breakdown you can use in investment theses, strategy decks, or competitive audits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation Reduction Act Implementation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImplementation of drug price negotiations under the Inflation Reduction Act threatens revenue for Bristol Myers Squibb, with Eliquis accounting for about $8.2 billion of BMS 2023 product sales and exposed to Medicare negotiation lists beginning in 2026–2028, pressuring 2026 guidance.\u003c\/p\u003e\n\u003cp\u003eIncreased federal pricing oversight and potential rebates reduce realized prices and margins in primary care; Medicare represents roughly one-third of U.S. prescription spending, amplifying revenue risk for top-selling drugs.\u003c\/p\u003e\n\u003cp\u003eTo mitigate projected margin compression, BMS is shifting investment toward earlier-stage oncology and immunology R\u0026amp;D—R\u0026amp;D spend rose to $7.3 billion in 2024—to build higher-margin, non-Medicare-exposed pipelines over the next 5–10 years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade and Supply Chain Policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing US-China tensions complicate API sourcing for Bristol Myers Squibb, which sourced an estimated 30-40% of certain APIs from Asia pre-2024; tariffs and export controls can raise input costs and lead to supply disruptions.\u003c\/p\u003e\n\u003cp\u003ePolitical pressure to near-shore or friend-shore has driven industry capex shifts; BMS announced a $300M-plus manufacturing expansion in the US\/EU in 2024 to secure oncology and immunology supply chains.\u003c\/p\u003e\n\u003cp\u003eBMS must actively manage diplomatic volatility through diversified suppliers, increased inventory buffers and contractual hedges to safeguard delivery to key markets, where oncology sales accounted for over 45% of 2024 revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEuropean Union Pharmaceutical Legislation Reform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProposed EU pharma reforms aim to shorten regulatory data protection from 8+2 years toward shorter terms to balance innovation and affordability, risking revenue impacts for Bristol Myers Squibb which reported €11.5bn in 2024 global oncology revenue (example regional share unknown); such political shifts push the company to accelerate clinical timelines and prioritize faster EU launch sequences to protect peak sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Research and Development Subsidies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment R\u0026amp;D subsidies—including NIH grants totaling about $45.8 billion in FY2024—fuel early-stage oncology work; Bristol Myers Squibb (BMS) leverages these funds and public-private collaborations to de-risk exploratory programs.\u003c\/p\u003e\n\u003cp\u003eBMS benefits from bipartisan initiatives like the Cancer Moonshot, which expanded funding to $2.2 billion in recent cycles and supports high-risk clinical trials aligned with BMS priorities.\u003c\/p\u003e\n\u003cp\u003eStrategic alignment with government research agendas lets BMS access public resources, share trial infrastructure costs, and accelerate therapies addressing national health priorities, improving pipeline efficiency and lowering development costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBMS leverages NIH grants and public collaborations to de-risk early oncology R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eCancer Moonshot funding (~$2.2B recent cycles) underpins high-risk trials\u003c\/li\u003e\n\u003cli\u003eAlignment with government goals reduces development costs and accelerates pipeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Security and Pandemic Preparedness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernments are boosting domestic health security—US federal funding for pandemic preparedness rose to about $15 billion in FY2025—prompting tighter oversight of vaccine and therapeutic manufacturing that affects BMS production and supply chains.\u003c\/p\u003e\n\u003cp\u003eThis political push compels BMS to engage in public-private partnerships and meet enhanced emergency-response standards to qualify for national procurement and stockpile inclusion.\u003c\/p\u003e\n\u003cp\u003eRetaining policy influence is critical: inclusion in national stockpiles and advance purchase agreements can materially affect revenue streams and reputation during future outbreaks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2025 US pandemic funding ~$15B impacting procurement rules\u003c\/li\u003e\n\u003cli\u003ePublic-private partnerships required for stockpile access\u003c\/li\u003e\n\u003cli\u003eStricter manufacturing oversight affects supply chain and compliance costs\u003c\/li\u003e\n\u003cli\u003ePolicy engagement preserves market access and revenue during crises\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare drug talks threaten $8.2B Eliquis; BMS pivots R\u0026amp;D amid supply, cost risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedicare drug-price negotiations (IRA) threaten Eliquis ~$8.2B 2023 sales, pressuring 2026 guidance; Medicare = ~33% US Rx spend. BMS shifted R\u0026amp;D to oncology\/immunology—R\u0026amp;D $7.3B in 2024—to offset margin risk. US-China tensions (30–40% API sourced from Asia pre-2024) and near-shore capex ($300M+ in 2024) raise supply\/cost risks. NIH\/Cancer Moonshot funding (~$45.8B FY2024; $2.2B) supports early R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEliquis sales (2023)\u003c\/td\u003e\n\u003ctd\u003e$8.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBMS R\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003e$7.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare share US Rx\u003c\/td\u003e\n\u003ctd\u003e~33%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPIs from Asia (pre-2024)\u003c\/td\u003e\n\u003ctd\u003e30–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS\/EU capex (2024)\u003c\/td\u003e\n\u003ctd\u003e$300M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH funding (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$45.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer Moonshot\u003c\/td\u003e\n\u003ctd\u003e$2.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Bristol Myers Squibb across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with each section backed by current data and trends for reliable, actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary for Bristol Myers Squibb that streamlines external risk discussion in meetings, is easily dropped into presentations, and allows quick note additions for region- or business-line–specific implications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of the Patent Cliff\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol Myers Squibb faces a patent cliff as Revlimid and Eliquis lose exclusivity around 2026–2027, risking a revenue shortfall—Revlimid generated about $12.4bn in 2022 and Eliquis ~$11.4bn—creating pressure to replace roughly $20–24bn in peak sales.\u003c\/p\u003e\n\u003cp\u003eBridging this gap depends on new launches (e.g., mavacamten, camzyos) and ADC candidates; investors watch pipeline readouts and commercialization execution to sustain dividends (2024 yield ~2.8%) and fund growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment and M\u0026amp;A Activity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, the US Fed funds rate near 5.25–5.50% raises BMS’s cost of capital, making debt-funded deals pricier and increasing annual interest expense on its ~40–50 billion USD gross debt load. High rates amplify the debt service burden for large acquisitions like Karuna and RayzeBio, pressuring free cash flow and leverage ratios. BMS must weigh balance-sheet strength—net leverage ~3.5x in 2024—against the need to buy innovation to offset an aging portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Rate Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBristol Myers Squibb, operating in 50+ countries, faces material FX risk as a stronger US dollar versus the euro and yen can reduce reported international revenue; in 2024 FX headwinds trimmed adjusted revenue growth by about 3-4% per company disclosures. Economic instability in emerging markets (LATAM, APAC) can produce adverse rates that erode translated sales and margins. The firm uses hedging, net investment hedges and localized treasury operations to stabilize earnings and reported EPS.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Spending and Payer Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic pressures on national health budgets and private insurers are squeezing reimbursement for high-cost specialty drugs; global health spending reached $10.3 trillion in 2024, prompting tighter formulary access for expensive oncology and immunology therapies.\u003c\/p\u003e\n\u003cp\u003ePayers increasingly demand outcomes-based pricing—about 18% of US Medicaid managed-care contracts incorporated value-based provisions by 2024—linking payment to real-world effectiveness.\u003c\/p\u003e\n\u003cp\u003eBMS must present robust health economics and outcomes research to defend formulary placement and counter biosimilar threats, as biosimilars cut originator prices by 20–40% in recent launches.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal health spend $10.3T (2024)\u003c\/li\u003e\n\u003cli\u003e~18% Medicaid managed-care value-based provisions (2024)\u003c\/li\u003e\n\u003cli\u003eBiosimilar price cuts 20–40%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Impacts on Manufacturing Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePersistent inflation in raw materials, energy, and specialized labor lifted COGS for complex biologics; U.S. pharma input prices rose about 5.8% y\/y in 2024, pressuring margin profiles for Bristol Myers Squibb which reported a 2024 gross margin around 71% but faces cost tailwinds.\u003c\/p\u003e\n\u003cp\u003ePolitical pressure on drug prices and proposed U.S.\/EU price controls can limit pricing power, narrowing net margins as inputs rise faster than allowed price increases.\u003c\/p\u003e\n\u003cp\u003eOperational efficiency and digital transformation—automation, continuous manufacturing, AI-driven yield optimization—are key levers; industry estimates suggest digital initiatives can cut manufacturing costs by 10–20% within 3–5 years.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInput inflation ~5.8% (2024)\u003c\/li\u003e\n\u003cli\u003eBMS 2024 gross margin ~71%\u003c\/li\u003e\n\u003cli\u003eDigital\/automation saves 10–20% manufacturing costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBMS at a crossroads: $20–24B patent cliff vs $40–50B debt, rising rates squeeze\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBMS faces a looming 2026–27 patent cliff (Revlimid ~$12.4bn 2022; Eliquis ~$11.4bn) needing ~20–24bn replacement; high rates (Fed 5.25–5.50% late 2025) raise cost of capital against ~$40–50bn gross debt and ~3.5x net leverage (2024); FX\/headwinds cut 2024 revenue ~3–4%; payers push value-based pricing (~18% Medicaid contracts 2024) and biosimilars cut prices 20–40%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevlimid\/Eliquis peak\u003c\/td\u003e\n\u003ctd\u003e$20–24bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross debt\u003c\/td\u003e\n\u003ctd\u003e$40–50bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet leverage (2024)\u003c\/td\u003e\n\u003ctd\u003e~3.5x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX drag (2024)\u003c\/td\u003e\n\u003ctd\u003e~3–4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput inflation (pharma 2024)\u003c\/td\u003e\n\u003ctd\u003e~5.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eBristol Myers Squibb PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Bristol Myers Squibb PESTLE document you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751553446265,"sku":"bms-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/bms-pestle-analysis.png?v=1772232968","url":"https:\/\/matrixbcg.com\/products\/bms-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}